Lexeo Therapeutics
(NASDAQ) LXEO
Lexeo Therapeutics Financials at a Glance
Market Cap
$383.97M
Revenue (TTM)
$0.00
Net Income (TTM)
-$87.50M
EPS (TTM)
-$1.45
P/E Ratio
-3.36
Dividend
$0.00
Beta (Volatility)
1.99 (High)
Dividend
$0.00
Beta (Volatility)
1.99 (High)
Price
$4.75
Volume
405,362.268
Open
$4.85
Price
$4.75
Volume
405,362.268
Open
$4.85
Previous Close
$4.89
Daily Range
$4.75 - $4.95
52-Week Range
$3.60 - $10.99
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
1.99 (High)
Price
$4.75
Volume
405,362.268
Open
$4.85
Previous Close
$4.89
Daily Range
$4.75 - $4.95
52-Week Range
$3.60 - $10.99
Estimated Earnings Date
Aug 13, 2026
LXEO News
LXEO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Lexeo Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
59
CEO
R. Nolan Townsend, MBA
Website
www.lexeotx.comHeadquarters
New York City, 10010, US
LXEO Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-47.48%
Return on Capital
-42.92%
Return on Assets
-34.95%
Earnings Yield
-29.76%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$383.97M
Shares Outstanding
78.52M
Volume
405.36K
Avg. Volume
877.52K
Financials (TTM)
Gross Profit
-$546.00K
Operating Income
-$97.79M
EBITDA
-$85.19M
Operating Cash Flow
-$97.99M
Capital Expenditure
-$432.00K
Free Cash Flow
-$98.42M
Cash & ST Invst.
$71.77M
Total Debt
$7.37M
Lexeo Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$546.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$383.97M
N/A
Market Cap/Employee
$5.12M
N/A
Employees
75
N/A
Net Income
-$20.20M
+38.2%
EBITDA
-$19.63M
+38.9%
Quarterly Fundamentals
Total Cash
$71.77M
-28.1%
Total Debt
$7.37M
-21.6%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$4.67M
-30.8%
Short Term Debt
$2.70M
+1.8%
Return on Assets
-34.95%
N/A
Return on Invested Capital
-41.41%
N/A
Free Cash Flow
-$21.18M
+2.5%
Operating Cash Flow
-$21.14M
+2.6%
